KYTX
Kyverna Therapeutics, Inc.
Key Financials
Operating Income
$-169827000
↓ 19.1%
EPS (Diluted)
$-3.64
↓ 9.3%
Total Liabilities
$61.5M
↑ 61.7%
Net Income
$-161307000
↓ 26.5%
Cash & Equivalents
$124.1M
↑ 28.4%
Total Assets
$293.8M
↓ 3.6%
Shareholders' Equity
$232.3M
↓ 12.9%
Operating Cash Flow
$-153712000.00
↓ 34.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/2/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 3 | 5/20/2026 | View on SEC |
| 8-K | 5/18/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KYTX |
| Company Name | Kyverna Therapeutics, Inc. |
| CIK | 1994702 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 5109252492 |